A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke

Trial Profile

A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs SUN 13837 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Sponsors Asubio Pharmaceuticals; Daiichi Sankyo Inc
  • Most Recent Events

    • 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to enrolment.
    • 11 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top